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At sites of angiogenesis, the expression of the key
angiogenesis regulator vascular endothelial growth
factor (VEGF) and its main receptor, VEGF receptor
2 (VEGFR-2), are strongly upregulated. Whereas the
processes controlling VEGF expression are well
described, the mechanisms underlying VEGFR-2
upregulation have remained unclear. We found that
endothelial VEGFR-2 expression is strongly reduced
in the absence of the G protein G13, resulting in an
impaired responsiveness to VEGF-A, a phenotype
that can be rescued by normalization of VEGFR-2
levels. G13-mediated VEGFR-2 expression involved
activation of the small GTPase RhoA and transcrip-
tion factor NF-kB, the latter acting via a specific bind-
ing site at position 84 of the VEGFR-2 promoter.
Mice with endothelial cell-specific loss of G13
showed reduced VEGFR-2 expression at sites of
angiogenesis and attenuated VEGF effects, resulting
in impaired retinal angiogenesis and tumor vascular-
ization. Taken together, we identified G-protein-
mediated signaling via G13 as a critical regulator of
VEGFR-2 expression during angiogenesis.
INTRODUCTION
Angiogenesis, the formation of new blood vessels from existing
ones, is not only centrally involved in embryonic development,
it also plays an important role during postnatal organ develop-
ment and various physiological and pathological remodeling
processes of the adult organism (Carmeliet and Jain, 2011).
The retina for example is avascular at birth, and a single superfi-
cial layer of blood vessels grows progressively from the center
toward the periphery from postnatal day (P) 1 until P7 (Gariano
and Gardner, 2005). Other examples of postnatal angiogenesis
are wound healing, revascularization, or tumor angiogenesis,
and pharmacological strategies targeting the latter have become
an important addition to the therapeutic repertoire for the treat-
ment of solid tumors (Carmeliet and Jain, 2011). Vascular endo-
thelial growth factors (VEGFs) are crucial regulators of pre- andDevepostnatal vascular development, they exert their angiogenic
effects by activating three cell-surface tyrosine kinase receptors
on endothelial cells, VEGFR-1 (FLT-1), VEGFR-2 (KDR/FLK-1),
and VEGFR-3 (FLT-4) (Adams and Alitalo, 2007; Shibuya and
Claesson-Welsh, 2006). All three receptors are highly expressed
by endothelial cells during development, and inactivation of any
receptor leads to vascular abnormalities and embryonic lethality
between embryonic day 8.5 and 10.5 in mice (Shibuya and
Claesson-Welsh, 2006). VEGF receptor 2 (VEGFR-2), mainly
activated by VEGF-A, plays a key role in the transduction of
angiogenic signals and controls endothelial cell morphology,
chemotaxis, and proliferation (Adams and Alitalo, 2007; Carme-
liet and Jain, 2011; Shibuya and Claesson-Welsh, 2006). In the
normal adult vasculature, VEGFR-2 is only detectable at
relatively low levels, but its expression is upregulated under
conditions requiring angiogenesis, for example, during wound
repair or tumor growth (Heidenreich et al., 2000; Millauer et al.,
1993; Shibuya and Claesson-Welsh, 2006; Zhang et al., 2004).
Themechanisms controlling VEGFR-2 expression are only partly
understood (Shibuya and Claesson-Welsh, 2006). The VEGFR-2
promoter contains four canonical E-box motifs, at least five Sp1
binding sites, an NF-kB site, and a TFII-I binding initiator element
(Illi et al., 2000; Patterson et al., 1995). Shear stress (Abumiya
et al., 2002; Urbich et al., 2003) or growth factors, such as basic
fibroblast growth factor (FGF2) and transforming growth
factor-b1, were shown to upregulate VEGFR-2 expression (Man-
driota et al., 1996; Murakami et al., 2011), whereas activated
Notch signaling has been shown to downregulate it (Lohela
et al., 2009).
G-protein-coupled receptors (GPCRs) have repeatedly been
implicated in angiogenesis (Dorsam and Gutkind, 2007; Richard
et al., 2001), but the underlying molecular mechanisms are
unclear. A role of the heterotrimeric G protein G13 was proposed
based on the fact that mice lacking the G protein a subunit of
G13, Ga13, die at embryonic day 9.5 because they fail to develop
an organized vascular system (Offermanns et al., 1997). This
defect in embryonic vessel development appeared to result
from the absence of Ga13 in endothelial cells, because the
same phenotype was observed in mice with endothelial cell-
specific Ga13 deficiency and because endothelial cell-specific
expression of Ga13 rescued the phenotype (Ruppel et al.,
2005). Though Ga13 has been involved in several endothelial
cell functions in vitro (Chen et al., 2009; Ruppel et al., 2005),
the mechanism of impaired vessel formation in the absence oflopmental Cell 25, 427–434, May 28, 2013 ª2013 Elsevier Inc. 427
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adult angiogenesis. Here, we used mice with tamoxifen-induc-
ible, endothelial cell-specific deletion of the gene encoding
Ga13 to study the role of this G protein a subunit in postnatal
vessel growth. We identified a pathway linking G13 via RhoA
and NF-kB to the regulation of VEGFR-2 expression as a mech-
anism by which G-protein-mediated signaling regulates
angiogenesis.
RESULTS
To test whether endothelial Ga13 and the closely related Ga12
play a role in postnatal angiogenesis, we studied retinal angio-
genesis on postnatal day 6 in mice that had received tamoxifen
injections on postnatal days 1–3 to induce tamoxifen-mediated
recombination of floxed alleles (Pitulescu et al., 2010). This
strategy resulted in efficient recombination of floxed alleles
in retinal and corneal vessels (Figure S1A available online).
Retinae of EC-Ga12/13-KOs showed reduced endothelial cell
coverage, vessel branching, and tip cell numbers (Figures
1A–1D), and also the number of filopodia per tip cell was
decreased (Figure S1B). Though retinal vessels looked slightly
more fragmented in EC-Ga13-KOs and EC-Ga12/13-KOs, we
did not find evidence for an increased rate of apoptosis in
mutant mice (data not shown). To investigate whether impaired
retinal angiogenesis was associated with an altered expression
of angiogenesis-related genes, we isolated endothelial cells
from lungs of 6-day-old mice and performed quantitative
RT-PCR. These analyses showed that the expression of
VEGFR-2 was selectively reduced in the absence of endothelial
Ga13, whereas expression of other angiogenesis-related genes
(Figure 1E) or G protein a subunits (Figure S1C) was not altered.
Decreased expression of VEGFR-2 was confirmed in retinae of
EC-Ga13-deficient mice on the mRNA level (Figure 1F) and on
the protein level (Figures 1G and 1H). To investigate whether
reduced VEGFR-2 expression in Ga13-deficient endothelial
cells was functionally relevant, we studied vessel ingrowth
into subcutaneously implanted Matrigel plugs in adult mice.
We found that Ga13-deficient endothelial cells were completely
unresponsive to VEGF-A added to the Matrigel, whereas
responses to FGF2, another potent inducer of angiogenesis,
were not significantly altered (Figures 1I–1K). Also the effects
of sphingosine-1-phosphate (S1P), a GPCR agonist that has
been implicated in angiogenesis (Obinata and Hla, 2012;
Skoura et al., 2007), were largely preserved (Figure S1D). These
findings indicate that reduced VEGFR-2 expression in Ga13-
deficient endothelial cells results in a selective impairment of
VEGF-A-mediated effects.
To further study the potential role of Ga13 in the regulation of
VEGFR-2 expression, we performed small interfering RNA
(siRNA)-mediated knockdown of Ga13 (Ga13-kd) in human umbil-
ical vein endothelial cells (HUVEC). As in murine cells, loss of
Ga13 resulted in reduced expression of VEGFR-2 on the mRNA
level (Figure 2A), and this was also true on the protein level (Fig-
ures 2B and 2C). Conversely, adenoviral overexpression of Ga13
increased VEGFR-2 expression (Figures 2D and 2E). Decreased
VEGFR-2 expression resulted in impaired VEGF-A-induced
phosphorylation of VEGFR-2 effectors, such as extracellular-
signal-regulated kinases 1/2 (ERK) or tyrosine kinase c-Src (Fig-428 Developmental Cell 25, 427–434, May 28, 2013 ª2013 Elsevier Inure 2F), whereas responses to other growth factors, for example,
FGF2 or insulin-like growth factor (IGF1), were not impaired (Fig-
ures S2A and S2B). Knockdown of other G protein a subunits,
such as Gai1, Gai2, and Gai3, did not affect VEGF-A-induced
ERK phosphorylation (Figures S2C and S2D). We also assessed
VEGF-A-induced tube formation after knockdown of Ga13 and
found it to be strongly reduced, whereas responses to FGF2
were preserved (Figures 2G–2I). Interestingly, knockdown of
Ga13 also lowered basal c-Src phosphorylation and tube forma-
tion, which led us to investigate whether these basal defects
were also due to reduced VEGFR-2 expression. Adenoviral
gene transfer of VEGFR-2 into Ga13-kd HUVEC normalized
VEGFR-2 levels (Figure 2J) and restored both tube formation
(Figures 2K and 2L) and c-Src phosphorylation (Figure S2E), sug-
gesting that downregulation of VEGFR-2 underlies these in vitro
defects. To investigate whether an acute reduction of endothelial
VEGFR-2 levels also explained the observed in vivo defects, we
studied retinal angiogenesis in mice with heterozygous inactiva-
tion of the Vegfr2 gene, a state that was shown to result in a
reduction of VEGFR-2 protein levels to approximately 50%
(Jakobsson et al., 2010). Tamoxifen treatment of Pdgfb-iCre;
Vegfr2fl/wt mice resulted in a retinal phenotype resembling that
of EC-Ga13-KOs (Figures S2F and S2G), suggesting that acute
reduction of VEGFR-2 expression indeed importantly contrib-
utes to the angiogenic defect in EC-Ga13-KOs. Because endo-
thelial Notch signaling has been implicated in the regulation
VEGFR-2 expression (Lohela et al., 2009), we also determined
basal and Delta-like ligand 4-induced Notch activity but did not
find differences after knockdown of Ga13 (Figure 2M). Also,
with respect to the expression of Notch-related genes, we did
not observe differences between the genotypes (Figure S2H).
To investigate whether Ga13 regulates VEGFR-2 expression
on the transcriptional level, we transfected HUVEC with a
luciferase reporter construct driven by a VEGFR-2 promoter
fragment containing base pairs 780 to +268 relative to the
transcriptional start (Mammoto et al., 2009) (VEGFR-2-Luc).
We found that Ga13-kd reduced VEGFR-2-Luc expression (Fig-
ure 3A), whereas overexpression of wild-type or constitutively
active Ga13 increased it (Figure 3B). Overexpression of Ga12, in
contrast, did not affect VEGFR-2-Luc activity (Figure 3B). We
next tested whether GPCR agonists that are known to signal
through Ga13 (Worzfeld et al., 2008) were able to reproduce
the effect of Ga13-overexpression. We found that both the prote-
ase thrombin and the lysophospholipid S1P enhanced VEGFR-2
promoter activity, and this effect was completely abrogated after
knockdown of Ga13 (Figure 3C). To investigate whether the small
GTPase RhoA, a well-known effector of the G12/13 family (Brown
et al., 2006; Worzfeld et al., 2008), mediates Ga13-depen-
dent VEGFR-2 promoter activity, we pretreated HUVEC with
C3-exoenzyme, which ADP-ribosylates and thereby inactivates
RhoA. Pretreatment with C3 exoenzyme completely abrogated
thrombin-induced effects (Figure 3D), indicating that RhoA is
required for Ga13-dependent VEGFR-2 expression. In line with
this notion, overexpression of constitutively active RhoA signifi-
cantly increased VEGFR-2-Luc activity, both in control HUVEC
and after knockdown of Ga13 (Figure S3A).
To further elucidate the molecular mechanism by which
Ga13/RhoA regulate VEGFR-2 expression, we employed deletion
mutants of the original 780/+268 VEGFR-2 luciferase reporterc.
Figure 1. Endothelial Ga13 Is Required for Postnatal Angiogenesis in Mice
(A–D) Exemplary photomicrographs (A) and statistical evaluation (B–D) of isolectin B4-stained retinae from 6-day-old mice after tamoxifen treatment on postnatal
days 1–3 (n = 6–12).
(E and F) Expression of angiogenesis-related geneswas determined by quantitative real-time PCR in lung endothelial cells (E) andwhole retinae (F) from 6-day-old
control mice and EC-Ga13-KOs (n = 6, all data normalized to GAPDH, control set to 1).
(G and H) Exemplary photomicrographs (G) and quantification (H) of immunostainings for VEGFR-2 and PECAM1 in retinae from 6-day-old control mice and
EC-Ga13-KOs.
(I–K) Exemplary photomicrographs (I) and statistical evaluation (J and K) of vessel ingrowth into subcutaneous Matrigel plugs containing VEGF-A (200 ng/ml) or
FGF2 (200 ng/ml) (n = 3).
n, number of mice per group; data are presented as mean ± SEM. See also Figure S1.
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Figure 2. Ga13 Controls VEGFR-2 Expression in HUVEC
(A) Effect of siRNA-mediated knockdown of Ga13 on VEGFR-2 expression as determined by quantitative real-time PCR.
(B–E) Effect of siRNA-mediated knockdown (B and C) or adenoviral overexpression (D and E) of Ga13 on VEGFR-2 protein levels (B and D, exemplary
immunoblots with a-tubulin as loading control; C and E, statistical evaluation after normalization to a-tubulin).
(F) Exemplary immunoblot showing the effect of Ga13-knockdown on VEGF-A (50 ng/ml)-induced phosphorylation of ERK or c-Src (a-tubulin as loading control).
(G–I) Exemplary photomicrograph (G, magnification 1003) and statistical evaluation (H and I) of basal, VEGF-A (50 ng/ml)-, and FGF2 (50 ng/ml)-induced tube
formation in HUVEC after knockdown of Ga13.
(J–L) Effect of adenoviral overexpression of VEGFR-2 (R2) on basal tube formation after Ga13-knockdown (J, immunoblot analysis of VEGFR-2 expression after
gene transfer; K and L, quantification of tube formation).
(M) Effect of Ga13-kd on basal and Delta-like ligand 4 (Dll4, 10 mg/ml)-induced activity of a Notch-dependent luciferase reporter construct. AD-Vir, adenovirus;
siContr, scrambled control siRNA; siGa13, siRNA directed against Ga13.
Figures represent data from 2–3 independent experiments; data are presented as mean ± SEM. See also Figure S2.
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225/+268, 130/+268, and 60/+268 (Figure 3E). We found
that Ga13-dependent VEGFR-2 expression was preserved in all
mutants, except the 60/+268 fragment (Figure 3F), suggesting
that the critical elements are located between 60 and 130, a
region that contains two Sp1 sites, two AP-2 sites, and an
NF-kB site (Patterson et al., 1995). Because Ga13/RhoA-medi-
ated signaling has been implicated in NF-kB activation in various
cell types (Brown et al., 2006; Martin et al., 2001; Profirovic et al.,
2005), we studied the potential involvement of NF-kB in Ga13-
dependent VEGFR-2 expression. We found that knockdown of430 Developmental Cell 25, 427–434, May 28, 2013 ª2013 Elsevier InGa13 abrogated thrombin-induced degradation of the NF-kB in-
hibitor IkBa (Figure 3G) and prevented thrombin-mediated lucif-
erase expression from an NF-kB-responsive reporter construct
(Figure 3H). Whereas thrombin-induced NF-kB activation was
obviously Ga13-dependent, the effects of GPCR-independent
activators of NF-kB, such as tumor necrosis factor-a (TNFa),
were not affected by knockdown of Ga13 (Figure 3H; Figures
S3B and S3C). Chromatin immunoprecipitation assays showed
that VEGFR-2 promoter sequences located between 28 and
144 could be precipitated with NF-kB, in particular after stimu-
lation with thrombin or TNFa (Figure S3D). Knockdown of Ga13c.
Figure 3. Ga13 Mediates Agonist-Induced VEGFR-2 Expression in HUVEC in a RhoA- and NF-kB-Dependent Manner
(A and B) Activity of a VEGFR-2 promoter (780/+268)-driven luciferase reporter construct (VEGFR-2-Luc) after siRNA-mediated knockdown of Ga13 (A) or after
overexpression of wild-type (WT) Ga12 or Ga13 as well as constitutively active (QL) Ga13 (B).
(C) Effect of Ga13-knockdown on agonist-induced stimulation of VEGFR-2-Luc activity in serum-starved HUVEC.
(D) Effect of RhoA-inhibitor C3 exoenzyme (C3, 0.5 mg/ml) on thrombin (10 U/ml)-induced VEGFR-2-Luc activity.
(E) Schematic diagram depicting the organization of the VEGFR-2 promoter.
(F) Effect of various deletion mutants of the original 780/+268 VEGFR-2-Luc construct on luciferase activity in the presence of control plasmid (vector) or
plasmids expressing wild-type (WT) or constitutively active (QL) Ga13. The size of the deletion mutants relative to the transcriptional start at position 1 is as
indicated; pGL3 is the empty vector.
(G) Effect of Ga13-knockdown on thrombin-induced IkBa degradation as determined by western blotting (GAPDH as loading control).
(H) Effect of Ga13-knockdown of thrombin (Thr, 10 U/ml)- and TNFa (TNF, 10 ng/ml)-induced activation of an NF-kB-responsive luciferase reporter (NF-kB-Luc).
(I) Thrombin (10 U/ml)-induced activation of VEGFR-2-Luc in the absence and presence of NF-kB inhibitor Ro106-9220 (Ro) or vehicle (veh).
(J) Effect of empty vector, wild-type Ga13 (Ga13WT), or constitutively active Ga13 (Ga13QL) on luciferase reporter constructs containing the VEGFR-2 promoter
fragment 225/+268 in its wild-type form (WT) or after mutation of the NF-kB site at 84.
Figures represent data from 2–3 independent experiments; data are presented as mean ± SEM. See also Figure S3.
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VEGFR-2 promoter sequences with NF-kB, whereas responses
to TNFa were preserved (Figure S3D). We furthermore found
that the NF-kB inhibitor Ro106-9920 reduced basal VEGFR-2
promoter activity and completely abrogated thrombin-inducedDeveeffects (Figure 3I) and that mutation of the NF-kB binding site at
position 84 of the VEGFR-2 promoter abrogated Ga13-depen-
dent transcription (Figure 3J). We conclude that Ga13 mediates
thrombin-induced expression of VEGFR-2 through a signaling
cascade involving RhoA-dependent NF-kB activation.lopmental Cell 25, 427–434, May 28, 2013 ª2013 Elsevier Inc. 431
Figure 4. Relevance of Ga13-Mediated VEGFR-2 Expression in Tumor Angiogenesis
(A–D) After subcutaneous inoculation of Lewis Lung carcinoma cells (LLC1) (A and B) or B16 melanoma cells (B16) (C and D), tumor growth (A and C) and final
tumor weight (B and D) were determined in mice of the indicated genotypes (n = 8–12).
(E–G) Vascularization of LLC1 tumors was determined after PECAM1 staining (E, exemplary photomicrograph, magnification 1003; F and G, statistical
evaluation) (n = 7–12).
(H) Immunostaining for VEGFR-2 in sections of LLC1 tumors grown in control mice and EC-Ga12/13-KO (left, exemplary photomicrograph, magnification 4003;
right, statistical evaluation). The intensity of VEGFR-2 staining was normalized to the intensity of PECAM1 staining to correct for the general rarefaction of
vessels (n = 4).
(I–L) LLC1 tumor growth curve (I), final tumor weight (J), and tumor vascularization (K and L) in control mice, EC-Ga13-KOs, and EC-Ga13-KOs overexpressing
wild-type Ga13 (Ga13WT) or a C-terminal deletion mutant of Ga13 (Ga13CD) (n = 6–10).
n, number of mice per group; data are presented as mean ± SEM. See also Figure S4.
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VEGFR-2 expression also contributed to tumor angiogenesis in
adult mice. Lewis lung larcinoma (LLC1) or B16F10 melanoma
(B16) cells were injected subcutaneously into the flank of control
mice and EC-specific mutant mice, and tumor growth and
vascularization were assessed. We found that EC-Ga13-KOs
and EC-Ga12/13-KOs showed significantly decreased tumor
growth (Figures 4A–4D), and postmortem analysis revealed
that tumor vascularization was reduced (Figures 4E–4G). Also,
tumor vessels grown in EC-Ga13-KOs and EC-Ga12/13-KOs
showed signs of normalization as judged by morphology (Fig-
ure S4A), and the percentage of functional (i.e., perfused) vessels432 Developmental Cell 25, 427–434, May 28, 2013 ª2013 Elsevier In(Figure S4B) and the degree of pericyte coveragewere increased
(Figures S4C and S4D). In addition, mutant vessels showed a
more coherent lining with VE-cadherin, whereas no changes
were observed with respect to apoptosis (data not shown).
Immunostainings indicated that also in tumor vessels VEGFR-2
expression was significantly reduced (Figure 4H). Because
Ga13-mediated proangiogenic effects have been suggested to
be due to GPCR-independent activation of Ga13 by growth
factor receptors (Shan et al., 2006), we tested whether a mutant
of Ga13 that lacks its C terminus and therefore is unable to
interact with GPCRs but still mediates effects of growth factor
receptor (Shan et al., 2006) would rescue the phenotype ofc.
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C-terminal deletion mutant Ga13-CD into EC-Ga13-KOs (Figures
S4E–S4H) and investigated the effect on VEGFR-2 promoter ac-
tivity in vitro as well as on tumor progression and vascularization
in vivo. In contrast to wild-type Ga13, the Ga13-CDmutant neither
had the ability to activate the VEGFR-2-Luc or NF-kB-Luc con-
structs in vitro (Figures S4I and S4J), nor did it normalize reduced
tumor growth and vascularization in EC-Ga13-KOs (Figures
4I–4L). These findings show that the positive regulatory effect
of Ga13 on VEGFR-2 promoter activity in vitro and angiogenesis
in vivo depends on its interaction with GPCRs.
DISCUSSION
It has long been known that endothelial Ga13 signaling plays an
important role in embryonic vessel development (Offermanns
et al., 1997; Ruppel et al., 2005), but the underlying mechanisms
and the relevance for adult vessel growth remained unknown.
We demonstrate here that Ga13-dependent NF-kB activation is
required to maintain VEGFR-2 expression in endothelial cells
and provide evidence that impaired responsiveness to VEGF-A
contributes to reduced postnatal angiogenesis in EC-Ga13-
KOs. To what degree altered VEGFR-2 expression contributes
to developmental angiogenesis and the embryonic death of
Ga13-deficient mice is currently unclear. Responses to other
angiogenic growth factors, such as FGF2, were not altered, sug-
gesting that the regulation of VEGFR-2 expression by Ga13 is
selective and specific. Though our studies in mice with inducible
endothelial-specific inactivation of one Vegfr2 allele indicate that
acute reduction of VEGFR-2 levels to 50% is sufficient to impair
angiogenic responses, we cannot exclude that other deficits of
Ga13-deficient endothelial cells contribute to the observed
phenotype. Ga13 has repeatedly been implicated in the regula-
tion of adhesion or migration in response to GPCR agonists,
such as thrombin, LPA, or S1P (Worzfeld et al., 2008), and
though the facilitating effect of S1P onMatrigel plug vasculariza-
tion was preserved in EC-G,13-KOs, reduced responsiveness to
other GPCR agonists might contribute to the phenotype.
GPCRs have been suggested to regulate angiogenesis by
modulating endothelial cell migration, permeability, or VEGF pro-
duction (Dorsam and Gutkind, 2007; Richard et al., 2001), but
their role in the regulation of VEGF receptor expression is not
well understood (Tsopanoglou and Maragoudakis, 1999). Our
in vitro studies identified the GPCR agonists thrombin and S1P
as stimulators of Ga13-dependent VEGFR-2 expression, two
substances that are present at high concentration in the blood
and therefore are well-suited tomodulate angiogenic processes.
LPA, in contrast, was without clear effects on VEGFR-2 expres-
sion (data not shown), but this does not necessarily exclude a
role of this phospholipid in vivo, because the expression pattern
of LPA receptors might differ between HUVEC and primary
endothelial cells. In line with a putative role of thrombin and
S1P, it was reported that mice lacking the thrombin receptor
PAR1 show a similar, albeit weaker, embryonic phenotype as
Ga13-KOs (Connolly et al., 1996), and also inactivation of S1P
receptors resulted in disturbed pre- and postnatal vessel growth
in mice (Obinata and Hla, 2012; Skoura et al., 2007).
As downstream mediators of Ga13-dependent VEGFR-2-
expression, we identify RhoA-dependent NF-kB activation andDeveshow that deletion of the proximal NF-kB binding site at 84,
relative to the transcriptional start, abrogates Ga13-induced
effects. Also, other activators of NF-kB signaling, for example,
TNFa, have been shown to upregulate VEGFR-2 expression
(Illi et al., 2000; Sainson et al., 2008), but these GPCR-indepen-
dent signaling pathways were not affected by knockdown of
Ga13. Though our expression analysis of angiogenesis-related
genes did not reveal major effects of Ga13-deficiency on other
NF-kB-regulated genes, such as Mmp9, Vegf-c, or Hif1a, we
can at this point not exclude that effects on other genes exist.
Our in vivo studies show that endothelial Ga13 is not only
required for physiological angiogenesis in the retina but is also
required for tumor angiogenesis, where lack of endothelial
Ga13 causes rarefaction and normalization of tumor vasculature
and, consecutively, reduced tumor growth. Importantly, inacti-
vation of endothelial Ga13 did not have major effects on other
basal endothelial functions, such as endothelial permeability or
baseline blood pressure regulation (Korhonen et al., 2009), mak-
ing this pathway an attractive target for safe and efficient interfer-
ence with angiogenic signaling.
EXPERIMENTAL PROCEDURES
Experimental Animals
Littermate EC-Ga13-KOs (Tie2CreERT2
pos; Gna13fl/fl; Gna12+/+), EC-Ga12/13-
KOs (Tie2CreERT2pos; Gna13fl/fl; Gna12/), Ga12-KOs (Gna13
fl/fl; Gna12/),
and control mice (Gna13fl/fl; Gna12+/+) were generated by intercrossing
Tie2CreERT2pos; Gna13fl/fl; Gna12+/ and Gna13fl/fl; Gna12+/ mice (seventh
generation backcross to C57BL/6). Genotyping was performed as described
previously (Korhonen et al., 2009). For induction of Cre-mediated recombina-
tion in adult mice, 6- to 10-week-old mice were injected intraperitoneally with
1 mg tamoxifen dissolved in 50 ml miglyol oil on five consecutive days (all
genotypes); experiments were performed 1–2weeks after the end of induction.
To induce Cre-mediated recombination in newborn mice, pups received
intraperitoneal injections of 50 mg tamoxifen in 50 ml miglyol on postnatal
days (P) 1, 2, and 3, followed by analysis on day 6 (Pitulescu et al., 2010).
For in vivoMatrigel plug angiogenesis assays, growth-factor-reducedMatri-
gel (BD Biosciences, Franklin Lakes, NJ, USA) solutions were prepared with or
without recombinant VEGF-A (200 ng/ml), bFGF/FGF2 (200 ng/ml), and S1P
(10 mM). The gel solutions (500 ml each) were injected subcutaneously into
the right and left flanks of anesthetized mice. After 14 days, Matrigel plugs
were harvested and frozen in O.C.T. compound (Tissue-Tek) for histological
analysis.
Tumor angiogenesis was analyzed in adult mice (8 to 12 weeks) in two tumor
models, B16F10 melanoma and Lewis lung carcinoma (LLC1). Adherently
growing murine B16F10 and LLC1 cells were harvested, and single-cell sus-
pensions of 1 3 106 cells in 100 ml PBS were injected subcutaneously into
the right flank of mice. Tumor volumes were measured every 2 or 3 days
with a caliper using the formula: V = 0.52 (d2 3 D), where d is the minor tumor
axis, and D is the major tumor axis. The mice were sacrificed at defined time
intervals after cell inoculation. Primary tumors were removed, weighed, and
processed for further histological analysis.
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